On May 26, 2023, EF Hutton reaffirmed its coverage of Agenus (NASDAQ:AGEN), a clinical-stage immuno-oncology company. EF Hutton maintains its Buy recommendation for the company.
According to Fintel, the average one-year price target for Agenus as of May 11, 2023 is 7.73. This represents an increase of 432.86% from its closing price of 1.45. The range of forecasts is from a low of 6.06 to a high of $8.72.
The projected annual revenue for Agenus is 93MM, which is a 1.79% decrease. The projected annual non-GAAP EPS is -0.73.
A total of 304 funds or institutions reported positions in Agenus, which is a decrease of 3 owner(s) or 0.98% in the last quarter. The average portfolio weight of all funds dedicated to AGEN is 0.07%, a decrease of 23.95%. Total shares owned by institutions increased in the last three months by 14.02% to 215,805K shares. The put/call ratio of AGEN is 0.05, indicating a bullish outlook.
Some of the largest shareholders of Agenus are Deep Track Capital, XBI – SPDR(R) S&P(R) Biotech ETF, Artal Group, and Citadel Advisors.
Agenus is a Lexington, MA-based company focused on discovering and developing immuno-oncology therapies that engage the body’s immune system to fight cancer. The Company aims to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through its AgenTus Therapeutics subsidiary), and proprietary cancer vaccine platforms.
Sources: Fintel
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
